Sign In
×Osool & Bakheet issues Q1 2024 earnings forecastArgaam20/04/2024
GIB Capital previews Q1 2024 earningsArgaam14/04/2024
GIB Capital previews Q1 2024 earningsArgaam14/04/2024
Argaam Reports
Jamjoom Pharma seen to post profit growth in Q4 2023Argaam Special20/02/2024
How did analysts view TASI performance, top picks for 2024?Argaam Special09/01/2024
How did analysts view Jamjoom Pharma’s Q3 financials?Argaam Special05/12/2023
TASI leaps 5.5% in 9M 2023; Etihad Atheeb, Elm top gainersِArgaam special 30/09/2023
Jamjoom Pharma revises up 2023 guidanceArgaam Special10/08/2023
Market Data
Last Trade | 130.00 |
Change | 0.60 |
Change (%) | 0.46 |
Open | 129.00 |
Low | 127.80 |
High | 131.20 |
Prev. Close | 129.40 |
Change (3M) | (8.71 %) |
Change (6M) | 24.05 % |
Volume | 141,647 |
Turnover | 18,392,770.00 |
Transactions | 1,363 |
Market Value | 9,100.00 |
Avg. Volume (3M) | 473,038.07 |
Avg. Turnover (3M) | 67,390,557.46 |
Avg. Transaction (3M) | 3,654.08 |
Change(12M) | n/a |
YTD | 13.04 % |
Event Date
|
Event
|
Venue
|
|
---|---|---|---|
25-03-2024
|
Conferences | - | |
25-03-2024
|
Financial results date | - | |
12-03-2024
|
General Assembly | - | |
07-11-2023
|
Financial results date | - | |
07-11-2023
|
Conferences | - | |
more |
Date | Research firm | Rating |
|
United Securities Company | Hold |
|
GIB Capital | Neutral |
|
Al Rajhi Capital | Overweight |
|
Al Rajhi Capital | Overweight |
Call Request